Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study Meeting Abstract
| Authors: | Hofmeister, C. C.; Chari, A.; Cohen, Y.; Spencer, A.; Voorhees, P. M.; Estell, J.; Venner, C. P.; Sandhu, I.; Jenner, M. W.; Williams, C.; Cavo, M.; Van De Donk, N. W. C. J.; Beksac, M.; Kuppens, S.; Bandekar, R.; Neff, T.; Heuck, C.; Qi, M.; Goldschmidt, H.; Landgren, O. |
| Abstract Title: | Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419401158 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.510.510 |
| Notes: | Meeting Abstract: 510 -- Source: Wos |
